Maria Eugenia Calvo Prieto (She/Her)

Undergraduate Student, The University of Hong Kong

About Maria Eugenia Calvo Prieto

Hello! I'm Eugenia, a second-year undergraduate student studying Biomedical Sciences at The University of Hong Kong. I'm passionate about healthcare and biotechnology, particularly stem cells, cancer biology, genomics and neuroscience.

I aspire to become a research scientist, designing experiments that lead to meaningful discoveries. I'm especially driven by the goal of promoting healthcare equity, and I hope my future work can contribute to solving global health challenges and improving access to effective treatments for all.

So far, for my research project the first summer, I investigated how we could reprogram immunity to target the most common type of liver cancer, known as hepatocellular carcinoma. My project focused on a promising cancer treatment strategy known as chimeric antigen receptors (CAR), which enable immune cells to better recognise and eliminate cancer. 

In my free time, you'll likely find me at a cafe with a friend or curled up with a good book (I especially enjoy historical fiction and mystery). 

I love meeting new people and exchanging ideas, so please feel free to connect! :)

Email: ecalvoprieto479@gmail.com

Linkedin: https://www.linkedin.com/in/maria-eugenia-calvo-prieto/

I am a/an:

Undergraduate Leadership & Research Scholar

University

The University of Hong Kong

Laidlaw Cohort Year

2025

Research Topic

Biochemistry Biological Sciences Biomedical Sciences Medicine Pharmaceutics Pharmacology Pharmacy

Area of Expertise

Biomedical Sciences

I am from:

Hong Kong Spain

I speak:

English Mandarin Spanish

My hobbies/interests are:

Art Photography Programming Reading Running/jogging Writing/blogging

I am open to participating in mentoring/buddy programmes

Yes

Intro Content

Essay Report Biochemistry Biomedical Sciences

Research Essay: Hoxb8-derived anti-GPC3 CAR expressing macrophages as a preclinical model for HCC immunotherapies

My research project involved engineering macrophages from Hoxb8 progenitors to express a GPC3-specific CAR for targeting hepatocellular carcinoma. The cells retained macrophage identity and CAR expression, offering a scalable platform to develop macrophage-based immunotherapies for HCC.

Influencer Of

Popular Content

Details

Online Elsewhere